Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | NSD2 | O96028 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | KHK | P50053 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24424957 | 0.75 | MEN1 (0.31) | ALDH1A1 | |
| SCHEMBL30260039 | 0.75 | MEN1 (0.31) | ALDH1A1 | |
| SCHEMBL31049154 | 0.74 | — | — | |
| SCHEMBL31368749 | 0.71 | ALDH1A1 (0.36) | ALDH1A1MAPK1KHK | |
| SCHEMBL29654317 | 0.70 | TLR9 (0.35) | — | |
| SCHEMBL25165297 | 0.69 | — | — | |
| SCHEMBL24424954 | 0.69 | KDM4E (0.33) | ALDH1A1 | |
| SCHEMBL22089649 | 0.68 | ALDH1A1 (0.32) | ALDH1A1KHK | |
| SCHEMBL31368737 | 0.68 | KDM4E (0.36) | L3MBTL1ALDH1A1NSD2MAPK1KHK | |
| SCHEMBL23751820 | 0.68 | TDP1 (0.32) | L3MBTL1ALDH1A1KHK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12331063-B2 | Hetero-bicyclic inhibitors of KRAS | INCYTE CORPORATION (US) | 2025-06-17 | — | — | US | disclosed |
| US-20220389033-A1 | HETERO-BICYCLIC INHIBITORS OF KRAS | INCYTE CORPORATION | 2022-12-08 | — | — | US | disclosed |
| US-20220389033-A1 | HETERO-BICYCLIC INHIBITORS OF KRAS | INCYTE CORPORATION | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12331063-B2 | Hetero-bicyclic inhibitors of KRAS | KRAS, NRAS, HRAS | L3MBTL1 2827/4885ALDH1A1 3026/4885NSD2 2941/4885 |
| US-20220389033-A1 | HETERO-BICYCLIC INHIBITORS OF KRAS | KRAS, NRAS, HRAS | L3MBTL1 2827/4885ALDH1A1 3026/4885NSD2 2941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.